Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Agonists

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    356 result(s) found for: Agonists. Displaying page 7 of 18.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2020-004815-29 Sponsor Protocol Number: ULA03 Start Date*: 2021-08-04
    Sponsor Name:Cardiorentis AG
    Full Title: Open-label, dose escalation study of ularitide for the investigation of hemodynamic effects in patients with pulmonary arterial hypertension (UPAH)
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-018904-94 Sponsor Protocol Number: 2010-018904-94 Start Date*: 2010-05-31
    Sponsor Name:FONDAZIONE SALVATORE MAUGERI - CLINICA DEL LAVORO E DELLA RIABILITAZIONE
    Full Title: EFFICACY AND SAFETY OF INTRAMUSCULAR NERIDRONATE IN OSTEOPOROTIC PATIENTS AFFECTED BY PARKINSON'S DISEASE
    Medical condition: Osteoporosis in patients affected by Parkinson's disaease at the stages 1-2-3-4 following Hoehn and Yahr criteria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005727-80 Sponsor Protocol Number: EMPA Start Date*: Information not available in EudraCT
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: Effect of insulin on renal maximum glucose transport capacity: interaction with empagliflozin. A not randomized pilot study.
    Medical condition: Patients with diabetes mellitus type 2
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001681-40 Sponsor Protocol Number: BY9010/IT-101 incl. amendment 1 Start Date*: 2004-10-25
    Sponsor Name:ALTANA Pharma AG
    Full Title: Comparison of inhaled ciclesonide (640 µg/day) and fluticasone propionate (1000 µg/day) in patients with moderate and severe per-sistent asthma
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    5.1 10003553 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021349-36 Sponsor Protocol Number: VRP100419 (CHDR1018) Start Date*: 2010-11-08
    Sponsor Name:Verona Pharma plc
    Full Title: Randomised, Double-Blind, Placebo-Controlled Evaluation of the Safety and Duration of Action of 2 Single Inhaled Doses, 0.036 mg/kg (12X) and 0.072 mg/kg (24X), of RPL554, a Dual PDE 3/4 Inhibitor,...
    Medical condition: Allergic Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001698-22 Sponsor Protocol Number: VRP110330 Start Date*: 2011-04-29
    Sponsor Name:Verona Pharma plc
    Full Title: EVALUATION OF THE EFFICACY AND SAFETY OF 6 REPEATED DAILY DOSES OF NEBULISED RPL554 0.018 mg/kg (6X) IN ALLERGIC ASTHMATICS
    Medical condition: Allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-013885-14 Sponsor Protocol Number: P06-10/BF2.649 Start Date*: 2009-11-12
    Sponsor Name:BIOPROJET
    Full Title: A randomized, multicenter 12-Week double-blind placebo-controlled study to assess the efficacy and safety of BF2.649 in Excessive Daytime Sleepiness in Parkinson?s disease followed by a 38-Week ope...
    Medical condition: Excessive daytime sleepiness in Parkinson?s Disease Somnolencia diurna excesiva en la enfermedad de Parkinson.
    Disease: Version SOC Term Classification Code Term Level
    12.0 10015595 Excessive daytime sleepiness LLT
    12.0 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002977-84 Sponsor Protocol Number: BECRO/RESP/ANASSA-PD Start Date*: 2020-10-16
    Sponsor Name:RESPIRENT Pharmaceuticals
    Full Title: A phase III, randomized, multicenter, parallel-group clinical trial for examining the therapeutic equivalence between Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmac...
    Medical condition: Asthma is a heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness an...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003561 Asthma, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001912-13 Sponsor Protocol Number: KTE-C19-105 Start Date*: 2018-04-24
    Sponsor Name:Kite Pharma, Inc.
    Full Title: A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL) (ZUMA-5)
    Medical condition: Relapsed or Refractory Indolent Non-Hodgkin Lymphoma (r/r) iNHL.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065856 Non-Hodgkin's lymphoma unspecified histology indolent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005288-31 Sponsor Protocol Number: MORF-057-201 Start Date*: 2022-07-04
    Sponsor Name:Morphic Therapeutic, Inc.
    Full Title: A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Adults with Moderately to Severely Active Ulcerative Colitis
    Medical condition: Moderate to Severe Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002997-30 Sponsor Protocol Number: RA-201902-2017958 Start Date*: 2021-01-25
    Sponsor Name:I.R.C.C.S. FONDAZIONE S.LUCIA
    Full Title: Dopaminergic Therapy for Frontotemporal Dementia Patients
    Medical condition: Frontotemporal Dementia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001051-19 Sponsor Protocol Number: CQAB149B2217 Start Date*: 2007-07-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A double-blind, randomized, cross-over, placebo-controlled, 2-part study to compare the effect of exercise and high-dose salbutamol on maximal heart-rate in patients with COPD following therapeutic...
    Medical condition: COPD (chronic Obstructive Pulmonary Disease)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001974-28 Sponsor Protocol Number: 767905/008 Start Date*: 2005-11-15
    Sponsor Name:GlaxoSmithKline R&D Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfu...
    Medical condition: Opioid-Induced Bowel Dysfunction
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FI (Completed) CZ (Completed) IE (Completed) GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003679-31 Sponsor Protocol Number: 2015_22 Start Date*: 2016-04-06
    Sponsor Name:Centre Hospitalier Régional et Universitaire de Lille
    Full Title: Conservative iron chelation as a disease-modifying strategy in Parkinson’s disease
    Medical condition: De Novo Parkinson’s disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) CZ (Completed) PT (Completed) FR (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-003117-41 Sponsor Protocol Number: CAIN457D2204 Start Date*: 2012-02-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo controlled, multiple dose study to evaluate the safety, tolerability, and efficacy of intravenous administration of secukinumab (AIN457) in patients with asthma ...
    Medical condition: Asthma not adequately controlled with inhaled corticosteroids and long acting beta-agonists
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001923-38 Sponsor Protocol Number: KTE-C19-108 Start Date*: 2019-05-06
    Sponsor Name:Kite Pharma, Inc
    Full Title: Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia
    Medical condition: Relapsed/Refractory Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10008977 Chronic lymphocytic leukemia recurrent LLT
    20.1 100000004864 10008978 Chronic lymphocytic leukemia refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004850-32 Sponsor Protocol Number: EFC13794 Start Date*: 2016-06-17
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: A 26-Week Randomized, Open-label, Active Controlled, Parallel-group, Study Assessing the Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination in Adults with Type 2 Diabe...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) EE (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002391-39 Sponsor Protocol Number: CLI-05993AB1-06 Start Date*: 2021-11-02
    Sponsor Name:Chiesi Farmaceutici S.p.A.
    Full Title: A 26 WEEK, RANDOMIZED, DOUBLE BLIND, MULTINATIONAL, MULTICENTRE, ACTIVE CONTROLLED, 2-ARM PARALLEL GROUP TRIAL COMPARING CHF 5993 100/6/12.5 μg pMDI (FIXED COMBINATION OF EXTRAFINE FORMULATION OF B...
    Medical condition: ASTHMA UNCONTROLLED ON MEDIUM DOSES OF INHALED CORTICOSTEROIDS IN COMBINATION WITH LONG-ACTING ß2- AGONISTS
    Disease: Version SOC Term Classification Code Term Level
    22.1 100000004855 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) SK (Completed) CZ (Completed) BG (Completed) PL (Completed) IT (Completed) LV (Completed) ES (Ongoing) FI (Completed) GR (Completed) NL (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-000162-22 Sponsor Protocol Number: 112025-002 Start Date*: 2015-05-04
    Sponsor Name:Laboratoire HRA Pharma
    Full Title: Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed b...
    Medical condition: Treatment of Cushing’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) BE (Completed) ES (Completed) HU (Completed) PL (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-004334-17 Sponsor Protocol Number: EORTC-1532-GUCG Start Date*: 2017-09-21
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer
    Medical condition: Hormone Naive Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned) AT (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 00:22:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA